Biocryst Pharmaceuticals Inc Dossier - Source-backed chat

Biocryst Pharmaceuticals Inc

BCRXNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.70

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.12Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1B

Enterprise Value $2.3B

Shares Outstanding 249.4M diluted

Next Earnings Date2 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioCryst Pharmaceuticals has transitioned into a commercial-stage biotech company with robust revenue growth driven by its flagship hereditary angioedema (HAE) oral therapy, ORLADEYO. Despite a significant GAAP net loss in Q1 2026 due to a one-time, non-cash acquired in-process research and development (IPR&D) charge from the Astria Therapeutics acquisition, the company's underlying non-GAAP operating profitability remains strong. The acquisition of Astria and its lead candidate, navenibart (a long-acting injectable plasma kallikrein inhibitor), strategically positions BioCryst to offer a comprehensive HAE treatment portfolio (daily oral and multi-month injectable options), capturing diverse patient preferences and establishing a highly defensible market position.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$20.82

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0020%

ORLADEYO growth slows due to intensifying competition from emerging HAE therapies (such as Ionis's donidalorsen or CRISPR-based treatments). The pediatric pellets manufacturing delay is prolonged, leading to market share loss in the pediatric segment. The integration of Astria Therapeutics results in higher-than-expected operating losses that drain cash reserves, and navenibart clinical trials encounter safety or efficacy setbacks, undermining the long-term pipeline valuation.

Base CaseCentral scenario

$20.8250%

Matches the consensus mean

ORLADEYO net revenues meet the guided range of $625 million to $645 million for 2026, representing steady double-digit organic growth (excluding the divested European operations). The pediatric pellets manufacturing issue is resolved with minimal long-term commercial disruption. Navenibart development progresses on track, and the company maintains non-GAAP operating expenses within the guided $450 million to $470 million range, achieving solid non-GAAP operating profits while funding its pipeline.

Bull CaseUpside scenario

$32.0030%

ORLADEYO continues to expand its market share, supported by consistent new prescriber additions and high patient retention rates. The successful resolution of the pediatric pellets manufacturing issue unlocks the pediatric market (ages 2 to 11), significantly expanding the addressable patient population. Navenibart clinical trials demonstrate best-in-class efficacy and safety, paving the way for a highly successful launch of a 3-to-6-month dosing regimen that challenges existing injectable incumbents. Non-GAAP operating margins expand rapidly, driving the company toward sustained GAAP profitability and substantial free cash flow generation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial execution of ORLADEYO with consistent double-digit year-over-year revenue growth.
Strategic acquisition of Astria Therapeutics (navenibart) creates a comprehensive HAE franchise spanning daily oral and long-acting injectable options.
Demonstrated non-GAAP operating profitability ($54.2 million in Q1 2026) and a solid cash cushion of $260.8 million to fund pipeline development.

Key Investment Risks

Intensifying competitive landscape in the HAE market from established and emerging injectable/genetic therapies.
Regulatory and execution risks, highlighted by the recent manufacturing issue delaying the pediatric pellets formulation.
Pipeline concentration and reliance on ORLADEYO to generate the vast majority of near-term revenues.

Thesis Invalidation Triggers

A significant downward revision in 2026 ORLADEYO revenue guidance.
Failure to resolve the pediatric pellets manufacturing issue or a clinical setback for navenibart.
Rapid cash burn exceeding non-GAAP operating expense guidance, threatening financial flexibility.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.